Abstract Heparan sulfate (HS) is present on the surface of endothelial and surrounding tissues in large quantities. It plays important roles in regulating numerous functions of the blood vessel wall, including blood coagulation, inflammation response, and cell differentiation. HS is a highly sulfated polysaccharide containing glucosamine and glucuronic/iduronic acid repeating disaccharide units. The unique sulfated saccharide sequences of HS determine its specific functions. Heparin, an analog of HS, is the most commonly used anticoagulant drug. Because of its wide range of biological functions, HS has become an interesting molecule to biochemists, medicinal chemists, and developmental biologists. In this review, we summarize recent progress toward understanding the interaction between HS and blood-coagulating factors, the biosynthesis of anticoagulant HS and the mechanism of action of HS biosynthetic enzymes. Furthermore, knowledge of the biosynthesis of HS facilitates the development of novel enzymatic approaches to synthesize HS from bacterial capsular polysaccharides and to produce polysaccharide end products with high specificity for the biological target. These advancements provide the foundation for the development of polysaccharide-based therapeutic agents.
Introduction
Heparin is a commonly used anticoagulant drug with annual sales close of up to $3 billion worldwide. Heparin is an analog of heparan sulfate (HS), a unique class of macromolecule that is widely expressed on the cell surface and in the extracellular matrix. HS is a highly sulfated polysaccharide consisting of the repeating disaccharide unit of 1→4-linked glucosamine and glucuronic/iduronic acid that may contain sulfo groups. A large body of evidence has demonstrated that this highly sulfated polysaccharide plays roles in regulating embryonic development and inflammatory responses, assisting viral and bacterial infections as well as blood coagulation (Esko and Selleck 2002; Hacker et al. 2005; Liu and Thorp 2002; Rosenberg et al. 1997; Taylor and Gallo 2006) . Under physiological pH, the sulfo groups exhibit considerable negative charges that influence binding properties to more than 100 proteins. Thus, HS is a molecule with a high density of information and significant potential for therapeutic applications. Understanding the mechanism employed by HS to regulate a specific biological process could aid the development of polysaccharide-based therapeutic agents with anticancer and antiviral activities and improve the pharmacological drug properties of anticoagulant heparin.
It is believed that HS achieves its selectivity by interacting with unique protein effectors to modulate the activities of these effectors. Decoding the nature of the interactions between HS and associated proteins has attracted considerable interest to delineate the involvement of HS in these important biological functions at the molecular level (Coombe and Kett 2005; Raman et al. 2005) . The prevailing hypothesis is that a HS polysaccharide with specific sulfation patterns determines the binding affinity and the extent of the activation of a target protein.
Our laboratories focus on understanding the HS biosynthetic pathway via biochemical and structural biology methods. In this review, we summarize recent developments regarding aspects of the biosynthesis of anticoagulant HS, the interaction of anticoagulant HS with thrombin and antithrombin (AT), the interaction of HS and its biosynthetic enzymes, and enzyme-based synthesis of HS. The interaction between HS and growth factors represent another important arena of HS research: the regulation of embryonic development, angiogenesis, and cancer growth. These topics were reviewed by several groups and they are beyond the scope of this article (Sanderson et al. 2004; Sasisekharan et al. 2002) .
The interactions of HS and blood-coagulating factors
The blood coagulation pathway is composed of a cascade of proteolytic reactions ultimately generating fibrin thrombi. The proanticoagulant activity of this cascade is balanced by several natural anticoagulant mechanisms. Binding of HS to AT represents the most important of these mechanisms. HS achieves its anticoagulant activity by interacting with AT, which then undergoes a conformation change, with the generation of the active form of AT that inhibits blood coagulation factors Xa and thrombin (IIa). Factor Xa or thrombin binding to AT results in the cleavage of the P1-P1′ scissile bond in the reactive center loop (RCL) loop trapping the coagulant protease in a covalently bound inactive intermediate with the AT molecule (Dementiev et al. 2004; Gettins 2002; Li et al. 2004) .
HS is found on the surface of endothelial cells. This suggests a physiologically relevant role in regulating levels of anticoagulant activity within the blood vessel. Pharmaceutical heparin is a product of mast cells that is isolated from porcine intestinal tissue with a stronger anticoagulant activity than endothelial HS. Heparin is considered a specialized form of HS with higher levels of sulfation per saccharide unit and iduronic acid content. For example, HS contains about 0.6 sulfo groups per disaccharide unit, while heparin contains 2.6 sulfo groups. Furthermore, about 40% of uronic acid in HS is iduronic, while 90% uronic acid in heparin is iduronic. Heparin has remained the drug of choice for the treatment of arterial and venous thrombotic disorders for more than a decade (Becker 2004) . This is largely due to the following: heparin is the only drug that inhibits the activities of both factor Xa and thrombin, heparin has a rapid anticoagulant response, and the excessive anticoagulant activity of heparin is reversible by protamine (Hirsh et al. 2005) . A major side effect of purified heparin, however, is thrombocytopenia. This condition is due to the induction of antibodies against the complex of platelet factor 4 and heparin (Kelton 2002) . The development of a new generation of heparin-based anticoagulant drugs with reduced side effects remains a high priority.
Structure and anticoagulant activity relationship
Only a fraction of HS binds to AT and exhibits anticoagulant activity. About 1-10% of the HS isolated from tissues binds to AT, while about 30% of pharmaceutical heparin binds to AT, suggesting that AT recognizes a unique structure of HS. Structural and functional studies have revealed that a short pentasaccharide domain of HS is critical for binding to AT (Jin et al. 1997; Li et al. 2004 ). Based on the structure of the AT-binding pentasaccharide, a new synthetic pentasaccharide anticoagulant under the trade name of Arixtra was approved by the FDA (Petitou and van Boeckel 2004) . However, the pentasaccharide unit only inhibits the activity of factor Xa mediated by AT. A much larger oligosaccharide is required to exhibit complete AT activity (Petitou et al. 1999; Petitou and van Boeckel 1992) .
Selectivity for HS by protein-binding partners stems from a number of different structural variables that affect the overall charge and conformation. The positions of sulfo groups and the length of the oligosaccharide are essential. In addition, the three dimensional positions of these sulfo groups can be affected by rotation around glycosidic linkage and through changes in ring conformation. Although GlcUA and GlcNAc are typically found in the 1 C 4 "chair" conformation, IdoUA is capable of being in either the 1 C 4 or 2 S 0 "skew boat" orientation (Mikhailov et al. 1996; Mulloy and Forster 2000) . Multiple conformations of the IdoUA units can present the sulfates on the surface of the HS in different arrangements such that the HS can have a variety of different structural and electrostatic properties that help to optimize protein interactions with the sulfates and optimize van der Waals surface contacts with the protein for increased substrate specificity.
The structural requirement for HS binding to AT was proved by chemically synthesizing a series of pentasaccharides with various combinations of sulfo groups and carboxyl groups (Petitou and van Boeckel 2004) . Removal of certain sulfo or carboxyl groups significantly compromised the binding affinity to AT, suggesting that these groups are critical (Fig. 1a) (Atha et al. 1985) . One of the critical motifs involved in binding to AT is the sulfation at the 3-OH position of this saccharide. Indeed, a pentasaccharide (Fig. 1a ) that lacks the 3-O-sulfo group from unit C has a decreased binding affinity to AT by nearly 20,000-fold (Atha et al. 1985) . Functional and structural studies investigating the interaction of HS with AT thus reveal a convincing example for demonstrating that a specific sulfated saccharide sequence controls the anticoagulant activity.
The necessary size for an oligosaccharide to inhibit thrombin activity is much longer (14-20 saccharides) than the pentasaccharide that is required to bind AT and inhibit factor Xa (Oosta et al. 1981) . A synthetic hexadecasaccharide (SR123781) that displays excellent anticoagulant activity against thrombin in vitro and in vivo was produced ). This oligosaccharide consists of an AT-binding domain, a nonsulfated linker region, and a thrombin-binding domain (Fig. 1b) . The structural requirement for binding of this oligosaccharide to thrombin, a cluster of sulfated saccharide units, appears to be less selective than for AT. Petitou et al. (1999) proved that the order of the three domains is essential for thrombin inhibition. Namely, the ATbinding domain is positioned at the reducing end of the nonsulfated linker and the thrombin-binding domain at the nonreducing end of the linker. It should be noted that the synthesized hexadecasaccharide is not a HS, rather a HS mimetic carrying sulfo groups. Several structural differences between a native HS oligosaccharide and the synthetic hexadecasaccharide are noted (Fig. 1b) . This HS mimetic contains methylated hydroxyls and glucose instead of glucosamine at the AT-binding domain (S12-S16). These glucose units contain 2-O-sulfo groups instead of the N-sulfo groups as would be present on glucosamine units. In addition, highly sulfated glucose units (thrombin-binding domain, S1-S4) mimic the binding of -IdoUA2S-GlcNS6S-in heparin, provided that the binding of HS to thrombin requires only highly sulfated saccharide units and thus is nonspecific. Despite structural differences, the binding of AT and thrombin to this hexadecasaccharide appears to mimic the interaction of AT, thrombin, and HS (Li et al. 2004) . Chemically synthesized HS hexadecasaccharides were not reported.
Crystal structure of ternary complex AT/thrombin/ hexadecasaccharide Details of the molecular interactions were ascertained from X-ray crystal structures of the binary complex of AT/HS and from ternary complexes of AT/thrombin and SR123781 (Dementiev et al. 2004; Jin et al. 1997; Li et al. 2004 ). These structures have revealed interactions between AT and heparin and thrombin that account for the increased level of inhibition of thrombin by AT in the presence of heparin (Fig. 2) .
Numerous contacts between the sulfo and carboxyl groups of the oligosaccharide with the proteins were observed in the ternary complex, in particular, in the region of AT and the AT-binding domain of the hexadecasaccharide (Fig. 2) . All of the saccharide units in the AT-binding domain are in the chair conformation with the exception of the iduronic acid (S15) at the reducing end, which is present in the skew boat conformation. There is a kink in the domain between this iduronic acid and the neighboring glucose (S14) that contains the specific 3-O-sulfo group. Indeed, the skew boat conformation of this iduronic acid unit is essential for binding to AT as demonstrated by Das et al. (2001) . The interactions between AT and HS involve Reducing and nonreducing ends are also indicated. S1, S2,..., and S16 define the position of the saccharide units the sulfo groups on the glucosamine equivalent glucose molecules at the 2,3 and 6 position and with carboxylate groups from the uronic acid saccharides. These interactions confirm the conclusions from the biochemical studies ( Fig. 1a) (Li et al. 2004 ). The functional groups that form interactions with AT are the 2-O-sulfo from S16, the carboxylate from S15, the 2-O-sulfo and 3-O-sulfo groups from S14, the carboxylate from S13, and the 6-O-sulfo group from S12. These specific interactions involve both side chain and backbone interactions with AT. The critical 3-O-sulfo group on S14 for AT binding is within hydrogenbonding distance to two lysines and one asparagine side chain. Given the numerous interactions between the pentasaccharide and AT, it is unclear why the 3-O-sulfo group from S14 is critical to binding. One possibility may be that locking this position down leads to the kink in the pentasaccharide with subsequent optimization of van der Waals contacts and ionic interactions with AT.
Biosynthesis of anticoagulant HS

Biosynthetic pathway
Cellular HS is present in the form of HS proteoglycan, which consists of a core protein and polysaccharide side chains. HS polysaccharide is attached to the core protein through a serine residue. The core protein functions as a carrier of the HS chains on the cell surface and in the extracellular matrix. Although the binding of HS polysaccharide side chains with protein effectors is believed to result in specific biological functions, the expression of core proteins plays a critical role in temporal and spatial regulation of cellular HS (Bernfield et al. 1999) . The biosynthesis of HS is performed by a complex pathway involving chain elongation and multiple modification steps (Fig. 3) . Synthesis is initiated with addition of a linkage region domain to a specific Ser residues on the protein followed by elongation steps to generate the unsulfated and unepimerized polysaccharide backbone consisting of GlcUA-GlcNAc disaccharide repeats (Lind et al. 1998; McCormick et al. 1998) .
After chain elongation, the polymer is modified by a series of sulfotransferases and a C 5 -epimerase (Fig. 3) . The first modification is N-sulfonation to form the N-sulfo glucosamine unit by N-deacetylase/N-sulfotransferase (NDST). NDST is a dual function enzyme that catalyzes the removal of the acetyl group from a GlcNAc residue and the transfer of a sulfo group to the amino group of the "deacetylated" unit. The C 5 -epimerase converts the neighboring GlcUA on the nonreducing side to an IdoUA unit. The chain modification proceeds with 2-O-sulfonation at the iduronic acid (or to a lesser extent at a GlcUA), 6-Osulfonation at the glucosamine, and 3-O-sulfonation at the glucosamine. These modifications are catalyzed by 2-Osulfotransferase (2-OST), 6-O-sulfotransferase (6-OST), and 3-O-sulfotransferase (3-OST), respectively (Fig. 3) . Biosynthesis of a polysaccharide with defined sequences
The mechanism for regulating synthesis of polysaccharides with defined saccharide sequences is essentially unknown because the synthesis is not a template-driven process. Nevertheless, it appears that structures of HS from a single cell line are consistent between generations, suggesting that the synthesis of HSs with unique saccharide sequences are genetically controlled ). In addition, synthesis of specific saccharide sequences can be regulated by the expression levels of specialized biosynthetic enzymes and the accessibility of the unique substrates for those specialized biosynthetic enzymes. These observations have led to a widely accepted hypothesis: The overall sulfation pattern of HS is dictated by the substrate specificities of HS biosynthetic enzymes. However, the detailed regulation of the sulfation pattern on a polysaccharide are not well understood.
The biosynthetic enzymes exhibit the substrate specificities at two different levels: the regioselectivity of the residue to be modified (the monosaccharide level) and the saccharide structures around the modified residue (at the oligosaccharide level). The regioselectivity for a given HS sulfotransferase is nearly exclusive (Habuchi et al. 1995; Ishihara et al. 1993; Kobayashi et al. 1996; Liu et al. 1996) . For example, 2-OST recognizes an iduronic acid (or a glucuronic acid) residue, and specifically transfers the sulfo group to the 2-OH position to form IdoUA2S (or GlcUA2S).
The best evidence of substrate specificities at the oligosaccharide levels is demonstrated by the fact that different isoforms recognize unique sulfation patterns around the modification site (Liu and Rosenberg 2002) . HS biosynthetic enzymes are present in multiple isoforms with the exception of 2-OST and C 5 -epimerase. NDST is present in four different isoforms, 6-OST is present in three different isoforms, and 3-OST in seven. The isoforms have slightly different substrate specificities and unique tissue specific expression patterns (Aikawa et al. 2001; Habuchi et al. 2000; Shworak et al. 1999; Xia et al. 2002) . It was hypothesized that cells regulate expression levels of different isoforms of the biosynthetic enzyme to synthesize HS with defined saccharide sequences to achieve unique biological functions ). Indeed, 3-OST isoforms are essential for the synthesis of heparin/HS with a variety of saccharide sequences that exhibit different substrate specificities, and the products display distinct biological functions as described in the section below. 6-OST isoforms are important for generating HS responsible for fibroblast growth factors and fibroblast growth factor receptor complex formation, although the substrate specificities among 6-OSTs are not experimentally distinguishable (Ashikari-Hada et al. 2004; Smeds et al. 2003) . The substrate specificities of NDST isoforms are more difficult to determine with current techniques, and thus, are largely unknown.
Regulation of the biosynthesis of anticoagulant HS
The key control of anticoagulant HS synthesis in vivo by cells is regulation of the expression level of HS 3-OST isoform 1 and isoform 5 (3-OST-1 and 3-OST-5) (Liu et al. 1996; Xia et al. 2002) . 3-OSTs transfer the sulfo group to the 3-OH position of a glucosamine unit to form a 3-Osulfated glucosamine. The detailed substrate specificities of 3-OST isoforms are described below. Overexpression of 3-OST-1 and 3-OST-5 in cells significantly elevates the level of anticoagulant HS (Duncan et al. 2004; Shworak et al. 1997) . The existence of multiple isoforms may explain why 3-OST-1 knockout mice failed to produce thrombotic phenotypes (HajMohammadi et al. 2003) .
Substrate specificities and mechanism of action of 3-OST isoforms
Substrate specificities of 3-OST isoforms HS 3-OST is present in seven isoforms, including 3-OST-1, -2, -3A, 3B, -4, -5, and 6 (Liu and Rosenberg 2002; Xia et al. 2002; Xu et al. 2005) . These enzymes catalyze the transfer of a sulfo group from the sulfo donor, 3′-phosphoadenosine-5′-phosphosulfate (PAPS), to the 3-OH position of a glucosamine unit. The amino acid sequences of the different isoforms have greater than 60% homology in the sulfotransferase domains. The isoforms transfer the sulfo group to the glucosamine residues that are linked to different saccharide units at the nonreducing end. The modifications predominately fall into three types (Fig. 4) . First, the sulfo group is transferred to the glucosamine unit that is adjacent to an unsulfated glucuronic acid (GlcUA). This type of modification is carried out by 3-OST-1. Second, the sulfo group is transferred to the glucosamine unit that is adjacent to a 2-O-sulfo iduronic acid (IdoUA2S). This type of modification is performed by 3-OST-2, -3A, -3B, -4, and -6. Among these, 3-OST-3A and 3-OST-3B have nearly identical amino acid sequence in the sulfotransferase domain, and thus, 3-OST-3 represents both 3-OST-3A and 3-OST-3B. Third, the sulfo group is transferred to the glucosamine unit that is adjacent to GlcUA, IdoUA, and IdoUA2S. This type of modification is carried out by 3-OST-5 (Chen et al. 2003) .
The unique substrate specificities of different 3-OST isoforms endow HS with distinct biological functions. As described above, 3-OST-1 and 3-OST-5 carry out critical 3-O-sulfation that permits the resultant HS binds to AT and exert anticoagulant activity. On the other hand, other 3-OST isoforms, including 3-OST-2, -3, -4, -5, and -6, carry out the critical 3-O-sulfation that generates HS with activity that promotes the infection of herpes simplex virus type 1 (HSV-1) (Shukla et al. 1999; Xu et al. 2005) . HS modified by these isoforms interacts with herpes virus envelope glycoprotein gD and serves as an entry receptor for the virus.
Crystal structures of 3-OST-1 and 3-OST-3
Because 3-OSTs play a critical role in controlling the biosynthesis of anticoagulant HS and unique substrate specificities among the isoforms, we investigated the mechanism of 3-OSTs using a structural biology approach coupled with site-directed mutagenesis Moon et al. 2004) . From these studies, several key amino acid residues were identified that contribute to the interactions with the sulfo donor PAPS and with polysaccharide substrates.
The crystal structure of 3-OST-1 in complex with 5′-phosphoadenosine 3′-phosphate (PAP) was solved at 2.5 Å. In addition, a ternary complex of 3-OST-3/PAP/tetrasaccharide substrate was solved at 1.9 Å Moon et al. 2004) . We have found that 3-OST-1 and 3-OST-3 have very similar overall structure. In this section, we focus our attention on describing the structure of 3-OST-3/PAP/tetrasaccharide (Fig. 5a,b) . The tetrasaccharide used in this study binds in a positively charged cleft. As seen in heparin binding to AT, a kink is induced by the protein between the two central residues I2 and G3 of the tetrasaccharide. The G1 residue forms interactions with the protein via the N-sulfo group, a bound sodium, and with the 3-hydroxyl. The I2 residue is found in the skew boat conformation and forms interactions with its carboxylate group and 3-hydroxyl. The substrate residue G3 is oriented in a catalytically relevant position with the 3 hydroxyl acceptor positioned 5 Å from the 5′-phosphate of the leaving group PAP and within hydrogen bonding distance of the proposed general base E184. In addition, the N-sulfo group is hydrogen-bonded to a backbone amide. At the nonreducing end of the tetrasaccharide is the terminal uronate residue (U4) with an unsaturated 4,5 carbon bond, which results from the polysaccharide cleavage by a heparin lyase. This residue dictates substrate specificity between 3-OST-1 and 3-OST-3 and forms ionic interactions with both the 2-O-sulfo group and the carboxylate group and a possible interaction with the 3′ hydroxyl. An unsulfated glucuronic acid at this position (as is the case for the 3-OST-1 substrate) would likely have a different ring conformation and thus would not likely form the same interactions. Mutations were made in these regions of 3-OST-3 and 3-OST-1 to support the conjecture that these residues determine substrate specificity. By understanding these subtle differences, we may be able to alter the substrate specificity of these enzymes to create more specific enzymes or novel sulfation patterns Fig. 4 Substrate specificity of 3-OST isoforms. The reactions catalyzed by 3-OST-1 and 3-OST-3 are shown. 3-OST-1 transfers the sulfo group from PAPS to the 3-OH position of a glucosamine unit (GlcNS±6S) that is linked to a glucuronic acid unit (GlcUA), thereby forming the 3-O-sulfated HS containing GlcUA-GlcNS3S±6S (an anticoagulant HS). 3-OST-3 transfers the sulfo group to the 3-OH position of a glucosamine unit (GlcNH 2 ±6S) that is linked to a 2-Osulfo iduronic acid unit (IdoUA2S), thereby forming the 3-O-sulfated HS containing IdoUA2S-GlcNH 2 3S±6S (an entry receptor for HSV-1). R represents proton (−H) or a sulfo group ÀSO À 3 À Á on heparin to improve the requirements for use of HS as therapeutic agents. For example, structure activity studies suggest that an extra 3-O-sulfo group at unit E in Fig. 1a improves the binding affinity to AT nearly 100-fold (Petitou and van Boeckel 1992) . A pentasaccharide consisting of two 3-O-sulfated glucosamine units has not yet been isolated from natural sources. The addition of a 3-O-sulfate group using genetically modified 3-OST enzymes could increase the specificity of the synthesized HS for AT.
Chemoenzymatic synthesis of HS with biological activities
Synthesis of HS oligosaccharides proved to be successful for the development of synthetic versions of HS-based anticoagulant drugs (Petitou and van Boeckel 2004) . This endeavor is largely based on the fact the side effects of heparin drugs stem from the structural heterogeneity of the polysaccharide (Petitou and van Boeckel 2004) .
Although chemical synthesis was the major route to obtain structurally defined heparin oligosaccharides, total chemical synthesis is time-consuming and costly. Further, chemical synthesis of nonanalog heparin and HS oligosaccharides, larger than hexasaccharides, is extremely difficult, if not impossible, based on currently available methods for carbohydrate synthesis. While a number of groups continue to pursue the synthesis of heparin (Avci et al. 2003; de Paz et al. 2006; Lee et al. 2004) , it is likely that chemical synthesis alone will be incapable of generating most larger oligosaccharide structures. The application of HS biosynthetic enzymes for generating large heparin and HS oligosaccharides with desired biological activities offers a promising alternative approach.
Attempts to synthesize HS using biosynthetic enzymes were reported. Although it is unclear whether the enzymatic approach synthesizes structurally defined polysaccharides, this method generates products with desired anticoagulant activity. Kuberan and Rosenberg utilized this approach to synthesize HS containing AT binding sites, with anticoagulant activity (Balagurunathan et al. 2003a,b; Kuberan et al. . While this approach demonstrated for the first time the feasibility of enzymatic synthesis of HS, only microgram amounts of product were generated, making extensive biological studies impossible. Recently, Lindahl et al. (2005) reported an alternative chemoenzymatic approach for the synthesis of anticoagulant heparin from heparosan, an Escherichia coli K5 capsular polysaccharide. This method utilized the C 5 -epimerase to convert D-glucuronic acid (GlcUA) to L-iduronic acid (IdoUA), followed by the chemical persulfonation, and finally selective desulfonation. While this approach affords gram quantities of a heparin-like polysaccharide with anticoagulant activity, unnatural saccharide units, such as 3-O-sulfo-D-glucuronic acid, are present in the product, suggesting a limitation in the selectivity of chemical sulfonation/desulfonation in HS synthesis. To this point, an effective approach for the synthesis of structurally defined large oligosaccharides is not yet available.
Following the same strategy, we have developed an efficient approach to synthesize the HS with desired biological activities in multimilligram scales. To achieve enzymatic synthesis of HS at a practical pharmaceutical level on a large scale, two obstacles need to be overcome: the availability of large amount of HS sulfotransferases and the inhibition effect of PAP, the desulfated product of PAPS. A proof of principle study was recently published using completely desulfated and N-sulfated heparin (compound 1) as a starting material (Fig. 6 ) to conduct the Osulfonation reactions (Chen et al. 2005) . First, highly active HS O-sulfotransferases were expressed in E. coli to provide sufficient quantities of sulfotransferases. Second, the sulfotransfer reactions were coupled with the PAPS regeneration system that was developed by the Wong group (Burkart et al. 2000) . This strategy eliminates the inhibition effect of PAP. The PAPS regeneration system utilizes arylsulfotransferase IV, which can converts PAP to PAPS as illustrated in Fig. 6b . In addition, the PAPS regeneration system utilizes the p-nitrophenol sulfate PNPS as the sulfo donor and requires only catalytic amounts of PAP, thereby reducing the cost of synthesis by more than 1,000-fold (Burkart et al. 2000) . Immobilized enzymes are used in this approach for reuse and improved thermal stability of the HS sulfotransferases. Thus the protocol can be efficiently scaled up. This method is capable of generating milligram quantities of specifically sulfated polysaccharide for desired biological activities: these include the anticoagulant activity Fig. 6 Pathways for synthesis of sulfated polysaccharides and the PAPS regeneration system. a Stepwise enzymatic synthesis of sulfated polysaccharides using HS sulfotransferases. Compounds 4a and 4b are prepared by inverting the order of sulfation steps: 4a is prepared by incubating compound 1 with 2-OST followed by 6-OST, whereas 4b is prepared by incubating compound 1 with 6-OST followed by 2-OST. b The reaction catalyzed by arylsulfotransferase IV (AST-IV) to generate PAPS. R represents −H or −SO 3 as measured by the anti-Xa and anti-thrombin activities (compounds 5 and 8), the activity in triggering FGF/FGF receptor signaling (compounds 4a and 4b), and binding to herpes simplex virus glycoprotein D (compound 6).
Conclusions
In addition to the anticoagulant activity of HS, many novel biological functions have emerged in recent years. These functions include roles of HS in regulating cancer growth and assisting viral and bacterial infections and inflammatory responses. Indeed, a low molecular weight heparin mimetic, PI88, is under phase II clinical trial to treat herpes simplex viral infections (Nyberg et al. 2004 ). In addition, PI88 also potentially serves as an anticancer drug, inhibiting the activity of heparanase in facilitating tumor metastasis (Ferro and Don 2003) . Knowledge of HS/heparin interactions with blood coagulating factors and how the biosynthesis of anticoagulant HS is performed will provide a model system for investigating the roles of HS in other related biological processes. It is clear that a chemoenzymatic approach is a viable method for generating the polysaccharides with different sulfation patterns and biological functions. The next challenge for HS/heparin research is the development of a technique to prepare "recombinant polysaccharides" with more precise structures to achieve high functional selectivity. The improved understanding of the regulation of HS biosynthesis and/or simplified synthetic techniques will help to achieve this goal. In the coming years of the glycomics era, continuing efforts on in HS/heparin research will likely lead to novel therapeutic agents.
